A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
Authors
Keywords
HIV-1, Maraviroc, Resistance, Env, gp120, V3 loop, CCR5 N-terminus, CCR5 ECLs
Journal
Retrovirology
Volume 10, Issue 1, Pages 43
Publisher
Springer Nature
Online
2013-04-20
DOI
10.1186/1742-4690-10-43
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
- (2012) Timothy J. Henrich et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
- (2012) Hamid Salimi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants
- (2012) J. J. Chiang et al. JOURNAL OF VIROLOGY
- V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc
- (2012) Reem Berro et al. VIROLOGY
- Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance
- (2012) Cleo G. Anastassopoulou et al. VIROLOGY
- Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV
- (2012) Kelechi Chikere et al. VIROLOGY
- Tyrosine Sulfation Influences the Chemokine Binding Selectivity of Peptides Derived from Chemokine Receptor CCR3
- (2011) John Z. Zhu et al. BIOCHEMISTRY
- Divergent and Site-Selective Solid-Phase Synthesis of Sulfopeptides
- (2011) Deni Taleski et al. Chemistry-An Asian Journal
- Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)
- (2011) Paul M McNicholas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Tyrosine-Sulfated CCR5-Mimetic Peptide Promotes Conformational Transitions in the HIV-1 Envelope Glycoprotein
- (2011) J. A. Kwong et al. JOURNAL OF VIROLOGY
- HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism
- (2011) M. Roche et al. JOURNAL OF VIROLOGY
- Alternative Coreceptor Requirements for Efficient CCR5- and CXCR4-Mediated HIV-1 Entry into Macrophages
- (2011) K. Cashin et al. JOURNAL OF VIROLOGY
- HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug
- (2011) O. Putcharoen et al. JOURNAL OF VIROLOGY
- HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
- (2011) Michael Roche et al. Retrovirology
- CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120–CD4 interactions and fusogenicity
- (2011) Jasminka Sterjovski et al. VIROLOGY
- Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41
- (2011) Cleo G. Anastassopoulou et al. VIROLOGY
- Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc
- (2010) Pierre Delobel et al. AIDS
- HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry
- (2010) John C. Tilton et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
- (2010) Timothy J Henrich et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection
- (2010) David A. Cooper et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of Emergent HIV Resistance in Treatment‐Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
- (2010) Paul McNicholas et al. JOURNAL OF INFECTIOUS DISEASES
- A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
- (2010) John C. Tilton et al. JOURNAL OF VIROLOGY
- HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
- (2010) J. M. Pfaff et al. JOURNAL OF VIROLOGY
- Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
- (2010) Robert A. Ogert et al. VIROLOGY
- An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
- (2010) Jasminka Sterjovski et al. VIROLOGY
- Coreceptors and HIV-1 Pathogenesis
- (2010) Paul R. Gorry et al. Current HIV/AIDS Reports
- Regulation of Chemokine Recognition by Site-Specific Tyrosine Sulfation of Receptor Peptides
- (2009) Levi S. Simpson et al. CHEMISTRY & BIOLOGY
- Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
- (2009) L. Gray et al. JOURNAL OF VIROLOGY
- Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc
- (2009) R. A. Ogert et al. JOURNAL OF VIROLOGY
- A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
- (2009) Samantha. H. Johnston et al. JOURNAL OF VIROLOGY
- Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
- (2009) Athe M. N. Tsibris et al. PLoS One
- Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
- (2009) C. G. Anastassopoulou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
- (2009) Pavel Pugach et al. VIROLOGY
- Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
- (2009) Reem Berro et al. PLoS Pathogens
- Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
- (2008) J. F. Demarest et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
- (2008) K. M. Kitrinos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection
- (2008) Raphael J. Landovitz et al. JOURNAL OF INFECTIOUS DISEASES
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject
- (2008) A. M. N. Tsibris et al. JOURNAL OF VIROLOGY
- Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
- (2008) Gerd Fätkenheuer et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started